Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality

Kathryn L. Pellegrini, Martin G. Sanda, Dattatraya Patil, Qi Long, María Santiago-Jiménez, Mandeep Takhar, Nicholas Erho, Kasra Yousefi, Elai Davicioni, Eric A. Klein, Robert B. Jenkins, R. Jeffrey Karnes, Carlos S. Moreno

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Objectives: To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP). Patients and Methods: Sig24 scores were calculated from previously collected gene expression microarray data from the Cleveland Clinic and Mayo Clinic (I and II). The performance of Sig24 was determined using time-dependent c-index analysis, Cox proportional hazards regression and Kaplan–Meier survival analysis. Results: Higher Sig24 scores were significantly associated with higher pathological Gleason scores in all three cohorts. Analysis of the Mayo Clinic II cohort, which included time-to-event information, indicated that patients with high Sig24 scores also had a higher risk of developing metastasis (hazard ratio [HR] 3.78, 95% confidence interval [CI]: 1.96–7.29; P < 0.001) or of PCSM (HR 6.54, 95% CI: 2.16–19.83; P < 0.001). Conclusions: The findings of the present study show the applicability of Sig24 for the prognosis of metastasis or PCSM after RP. Future studies investigating the combination of Sig24 with available prognostic tests may provide new approaches to improve risk stratification for patients with prostate cancer.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalBJU international
Volume119
Issue number6
DOIs
StatePublished - Jun 2017

Keywords

  • #PCSM
  • #ProstateCancer
  • biomarker
  • metastasis

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality'. Together they form a unique fingerprint.

  • Cite this

    Pellegrini, K. L., Sanda, M. G., Patil, D., Long, Q., Santiago-Jiménez, M., Takhar, M., Erho, N., Yousefi, K., Davicioni, E., Klein, E. A., Jenkins, R. B., Karnes, R. J., & Moreno, C. S. (2017). Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU international, 119(6), 961-967. https://doi.org/10.1111/bju.13779